The world’s most populous country is facing a double healthcare crunch with a rapidly aging population and an explosion in the rate of non-communicable diseases such as diabetes, heart disease, and lung disease. Addressing these diseases will require a robust pharmaceutical system that is able to produce quality, effective, and affordable medicines
